Orsini, a specialty pharmacy known for its work in rare disease care, has been named a specialty pharmacy partner for LISRAYA (brepocitinib), a newly...
Amylyx Pharmaceuticals has announced positive top-line results from its pivotal Phase 3 LUCIDITY trial evaluating avexitide, a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist being...
Zydus Lifesciences Limited, in collaboration with the Indian Council of Medical Research (ICMR), has announced the successful completion of Phase II Proof-of-Concept trials and approval...